Advertise on podcast: CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Please visit answersincme.com/ZSN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Wanda Phipatanakul, MD, MS. In this activity, an expert in pediatric asthma discusses how to identify type 2 inflammation and tailor biologic therapy for pediatric patients with asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Outline the role of multidisciplinary teams in optimizing outcomes for pediatric patients with type 2 inflammatory asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/860/102251349-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Charles L. Daley, MD, ATSF, FCCP; and David E. Griffith, MD, ATSF, FCCP. In this activity, experts in MAC lung disease discuss emerging first-line treatments and guideline-concordant, patient-centered strategies to individualize care for patients with newly diagnosed or refractory disease. Upon completion of this activity, participants should be better able to: Review the clinical profiles of emerging first-line treatments for Mycobacterium avium complex (MAC) lung disease in the context of standard of care regimens; Apply guideline-concordant strategies to develop individualized treatment plans for patients with newly diagnosed and refractory MAC lung disease; and Outline patient-centered strategies to enhance outcomes for patients with MAC lung disease receiving pharmacologic treatment.

Please visit answersincme.com/860/160204757-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Karen P. Acker, MD; and Donna Hallas, PhD, PPCNP-PC, CPNP, PMHS, FAANP, FAAN. In this activity, experts in RSV prevention discuss the latest evidence and practical strategies for implementing immunoprophylaxis and coordinating caregiver counseling across the care continuum. Upon completion of this activity, participants should be better able to: Discuss the rationale for RSV immunoprophylaxis for preventing RSV disease in early infancy. Integrate guideline recommendations into shared clinical decision-making for the prevention of RSV in infants. Outline the complementary roles of pre- and postnatal clinicians in coordinating RSV immunization counseling across the care continuum. Implement coordinated communication strategies to support caregiver decision-making about RSV prevention. This symposium is not sponsored, endorsed or accredited by the American Academy of Pediatrics.

Please visit answersincme.com/860/MED-HEM-04146-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tuan H. Vu, MD. In this activity, experts in generalized myasthenia gravis discuss evidence-based strategies for optimal use of C5-targeted therapies. Upon completion of this activity, participants should be better able to: Assess the rationale for C5-targeted therapies in patients with generalized myasthenia gravis (gMG). Individualize C5-targeted therapy for appropriate patients with gMG based on available evidence. Formulate patient-centered, evidence-based strategies for optimizing integration of C5-targeted therapies for gMG as they become available. This activity will be held during the AANEM Annual Meeting. It is not part of the official scientific program of the AANEM.

Please visit answersincme.com/QRE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Theresa W. Guilbert, MD, MS. In this activity, an expert in childhood asthma discusses the use of biologics for moderate to severe pediatric asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Review the clinical profiles of biologic therapies for type 2 inflammatory asthma in pediatric patients. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/TZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James E. Galvin, MD, MPH. In this activity, an expert in Alzheimer’s disease (AD) discusses treatment of early AD with anti-amyloid therapies. Upon completion of this activity, participants should be better able to: Review the latest advances in anti-amyloid therapies for the treatment of early Alzheimer’s disease (AD; Assess the current evidence on anti-amyloid therapies, including maintenance strategies, for the treatment of early AD; and Outline strategies to integrate the latest advances in anti-amyloid therapies to practice to improve long-term outcomes for patients with early AD.

Please visit answersincme.com/860/MED-RESP-04317-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cecelia Damask, DO; Zara M. Patel, MD; Maria Colandrea, DNP, NP-C, CORLN, FAANP; and Dan Shaltanis. In this activity, experts in chronic rhinosinusitis with nasal polyps discuss the latest evidence and practical strategies for optimizing the use of biologic therapies and delivering patient-centered care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the use of biologic therapies to treat patients with chronic rhinosinusitis with nasal polyps (CRSwNP); Differentiate among biologic therapies for patients with CRSwNP based on clinical evidence; and Outline strategies to optimize the holistic management of CRSwNP.

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.

Please visit answersincme.com/AQE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nirmala Gonsalves, MD, AGAF, FACG. In this activity, an expert in esophageal gastroenterology, discusses strategies for pharmacological treatment of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Specify the current guideline recommendations for the pharmacologic treatment of eosinophilic esophagitis (EoE); Formulate personalized strategies to use approved pharmacologic options during initiation and maintenance phases of EoE management; and Apply multidisciplinary strategies to optimize long-term management of patients with EoE using approved pharmacologic treatments.

Please visit answersincme.com/WWD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter Lio, MD, FAAD; Sarah L. Chamlin, MD; and Heather Moery. In this activity, experts in pediatric atopic dermatitis discuss earlier use of systemic therapy to improve long-term disease control and patient-centered outcomes. Upon completion of this activity, participants should be better able to: Identify the need for systemic therapy among pediatric patients with moderate-to-severe atopic dermatitis (AD); Recognize pediatric patients with moderate-to-severe AD for whom biologic therapy is an appropriate, evidence-based option; Review shared decision-making considerations regarding biologic therapy for pediatric patients with moderate-to-severe AD; and Integrate strategies to optimize biologic treatment for pediatric patients with moderate-to-severe AD.

Please visit answersincme.com/860/2026-MC-001884-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marc Serota, MD; Kristin Sokol, MD, MS, MPH; and Michelle Tarbox, MD. In this activity, experts in chronic spontaneous urticaria (CSU) discuss strategies to reduce diagnostic delays and how to personalize care beyond antihistamines. Upon completion of this activity, participants should be better able to: Recognize the impact of delayed diagnosis on disease control in patients with CSU; Review key inflammatory pathways—including type 2 inflammation—in CSU pathogenesis and how targeted therapies modulate them; Assess the latest clinical data for targeted therapies for the treatment of CSU; and Apply evidence-based strategies to personalize the management of antihistamine-refractory CSU.

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/BJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rajesh Gandhi, MD. In this activity, an expert in infectious diseases discusses novel oral antiretroviral therapy (ART) for the management of human immunodeficiency virus (HIV). Upon completion of this activity, participants should be better able to: Recognize the rationale for novel oral ART regimens in the management of virologically suppressed HIV infection; Review the clinical impact of novel emerging oral ART regimens for patients with virologically suppressed HIV infection; and Formulate patient-centered strategies for optimizing the personalized management of oral ART for patients with virologically suppressed HIV infection.

Please visit answersincme.com/DDT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Robert Haddad, MD. In this activity, an expert in medical oncology discusses locally advanced head and neck squamous cell carcinoma (LA HNSCC). Upon completion of this activity, participants should be better able to: Discuss the clinical implications of the latest data for approved and recommended regimens for resectable LA HNSCC in the pre- and postoperative settings; Outline strategies to integrate immunotherapy into pre- and postoperative settings for resectable LA HNSCC, in the context of conventional treatment; and Apply multidisciplinary team approaches to effectively manage patients with LA HNSCC across pre- and postoperative treatment phases.

Please visit answersincme.com/TNH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nick H. Kim, MD and Vallerie V. McLaughlin, MD. In this activity, experts in cardiovascular medicine and pulmonology discuss pulmonary arterial hypertension (PAH). Upon completion of this activity, participants should be better able to: Recognize the importance of treatment escalation for appropriate patients with PAH; Design risk-based treatment escalation plans for patients with PAH; Review the clinical impact of guideline-recommended therapies for risk-based treatment escalation in PAH; and Propose practical considerations to enhance outcomes for patients with PAH requiring treatment escalation.